QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
QQQ   415.91 (-1.77%)
AAPL   164.21 (-1.69%)
MSFT   398.88 (-1.33%)
META   483.13 (-3.72%)
GOOGL   153.17 (-1.82%)
AMZN   174.75 (-2.49%)
TSLA   148.59 (-0.89%)
NVDA   808.23 (-4.54%)
AMD   148.30 (-4.37%)
NIO   3.81 (-4.75%)
BABA   68.50 (-0.55%)
T   16.32 (-0.06%)
F   12.10 (+0.33%)
MU   106.98 (-4.42%)
GE   148.32 (-3.02%)
CGC   7.94 (+1.40%)
DIS   111.40 (-0.92%)
AMC   3.22 (+10.27%)
PFE   25.80 (+1.61%)
PYPL   61.81 (-0.47%)
XOM   119.97 (+1.22%)
Free Trial
OTCMKTS:OPHLY

Ono Pharmaceutical (OPHLY) Stock Price, News & Analysis

→ Biden replacement revealed? (From Paradigm Press) (Ad)
Free OPHLY Stock Alerts
$4.88
-0.11 (-2.20%)
(As of 04/18/2024 ET)
Compare
Today's Range
$4.78
▼
$4.94
50-Day Range
$4.98
▼
$5.60
52-Week Range
$4.85
▼
$6.85
Volume
209,660 shs
Average Volume
96,788 shs
Market Capitalization
N/A
P/E Ratio
1.07
Dividend Yield
339.28%
Price Target
N/A
Stock AnalysisAnalyst ForecastsChartFinancialsHeadlinesSEC FilingsShort Interest
OPHLY stock logo

About Ono Pharmaceutical Stock (OTCMKTS:OPHLY)

Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer's disease; Ongentys tablets for Parkinson's disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis. In addition, it develops products for hepatocellular and urothelial carcinoma; ovarian, bladder, prostate, pancreatic, gastric, esophageal, colorectal, thyroid, cell lung, and breast cancer; acute myeloid leukemia; solid tumors; myelodysplastic syndrome; melanoma; T-cell lymphoma; tachyarrhythmia; pemphigus; scleroderma; seizures; diabetic polyneuropathy; neurodegenerative diseases; autoimmune diseases; narcolepsy; and thrombosis. The company has a collaboration with Adimab, LLC to discover novel antibody drugs; a research collaboration with Turbine Ltd. to identify and validate novel oncology targets; Harvard University for validating novel therapeutic targets; and a strategic drug discovery collaboration with Sibylla Biotech in central nervous system disorders. The company was founded in 1717 and is headquartered in Osaka, Japan.

OPHLY Stock Price History

OPHLY Stock News Headlines

April 15, 2024 | americanbankingnews.com
Short Interest in Ono Pharmaceutical Co., Ltd. (OTCMKTS:OPHLY) Drops By 23.8%
March 6, 2024 | msn.com
Ono signs licence deal with NEX-I for cancer therapy
April 19, 2024 | Darwin (Ad)
Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report
Eager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click! Why This Report Is Your Gateway to Success: * Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story. * In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock. (**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.)
February 26, 2024 | finance.yahoo.com
Fate Therapeutics Inc (FATE) Reports Fourth Quarter and Full Year 2023 Financial Results
February 19, 2024 | markets.businessinsider.com
InveniAI Announces Collaboration with Ono Pharmaceutical for Target Discovery
February 15, 2024 | finance.yahoo.com
Ono Pharmaceutical Co., Ltd. (OPHLY)
February 14, 2024 | globenewswire.com
Numab Therapeutics and Ono Pharmaceutical Announce an Option and Collaboration Agreement to Develop Multi-specific Antibody NM49 for Treatment of Cancer
February 10, 2024 | barrons.com
Ono Pharmaceutical Co. Ltd.
April 19, 2024 | Darwin (Ad)
Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report
Eager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click! Why This Report Is Your Gateway to Success: * Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story. * In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock. (**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.)
January 30, 2024 | markets.businessinsider.com
Ono Pharmaceutical earnings preview: what Wall Street is expecting
January 9, 2024 | finance.yahoo.com
Call for Application to Researchers for Joint Research Project between Ono Pharmaceutical and BioMed X
December 19, 2023 | finanznachrichten.de
The BioMed X Institute: BioMed X Institute and Ono Pharmaceutical Launch New Collaboration in Cancer Research
November 28, 2023 | finance.yahoo.com
Nikkei Edges 0.2% Lower Amid JPY Strength
November 27, 2023 | finance.yahoo.com
China Shares Open Lower; Infrastructure Stocks Weigh
October 5, 2023 | msn.com
Ono Pharmaceutical Co. Ltd - ADR (OPHLY) Price Target Increased by 10.78% to 7.59
August 31, 2023 | finance.yahoo.com
Twist Bioscience Enters into Agreement with Ono Pharmaceutical to Discover Novel Antibodies for Autoimmune Diseases
August 31, 2023 | markets.businessinsider.com
Twist Bioscience To Develop Novel Antibodies With Ono Pharma
August 9, 2023 | finance.yahoo.com
Q2 2023 Fate Therapeutics Inc Earnings Call
August 3, 2023 | msn.com
Ono Pharmaceutical Co. Ltd - ADR (OPHLY) Price Target Decreased by 29.33% to 6.89
March 23, 2023 | technews.tmcnet.com
Macomics and Ono Pharmaceutical Partner to Discover and Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer
November 1, 2022 | benzinga.com
Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets
September 19, 2022 | finance.yahoo.com
3 Reasons Why Ono Pharmaceutical Co. (OPHLF) Is a Great Growth Stock
August 30, 2022 | seekingalpha.com
Fate Therapeutics: Yes For Speculators, No For Defensive Investors
July 18, 2022 | benzinga.com
Ono Pharmaceutical (OTC:OPHLY), Earnings Estimates, EPS, and Revenue
July 18, 2022 | benzinga.com
Ono Pharmaceutical (OTC:OPHLY), Analyst Ratings, Price Targets, Predictions
July 7, 2022 | uk.finance.yahoo.com
Can Ono Pharmaceutical Co ride out the impact of economic shocks?
January 23, 2022 | nasdaq.com
Ono Pharmaceutical Co. Ltd ADR (OPHLY)
See More Headlines
Receive OPHLY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ono Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Sector
Medical
Industry
Drug Manufacturers - General
Sub-Industry
N/A
Current Symbol
OTCMKTS:OPHLY
CUSIP
N/A
CIK
940821
Web
www.ono.co.jp
Phone
(166) 263-5670
Fax
N/A
Employees
3,761
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
1.07
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Gyo Sagara (Age 66)
    CEO, President & Representative Director
    Comp: $894.2k
  • Mr. Masaki Ito
    Corp. Offcr. and Div. Dir. of Corp. Strategy & Planning, Bus. Mgmt., Fin. & Acc. Dept. and Corp. Tax
  • Takehiro Yamada
    Corporate Officer & Senior Director of Risk & Compliance Mgmt. Dept. and Risk Mgmt. Promotion Office
  • Masayuki Tanigawa
    Corporate Officer & Executive Director of Corporate Development & Strategy
  • Mr. Toichi Takino Ph.D. (Age 56)
    Senior Managing Executive Officer, Head of Research Division & Director
  • Mr. Toshihiro Tsujinaka (Age 60)
    Sr. EO, Executive Director of Sustainability Promotion Corporate Strategy & Planning and Director
  • Hiromu Habashita Ph.D.
    Corporate Officer, Dep. Executive Dir. of Discovery & Research and Research Center of Immunology
  • Kiyoaki Idemitsu (Age 60)
    Managing Executive Officer, GM of Development Division & Director
  • Shinji Takai M.D.
    Ph.D., Corporate Officer & Head of Medical Affairs
  • Satoshi Takahagi
    Corporate Officer and Executive Director of Sales, Marketing & Primary Care Business Division

Key Competitors

View All Competitors

OPHLY Stock Analysis - Frequently Asked Questions

Should I buy or sell Ono Pharmaceutical stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ono Pharmaceutical in the last year. There are currently 1 sell rating for the stock. The consensus among Wall Street research analysts is that investors should "sell" OPHLY shares.
View OPHLY analyst ratings or view top-rated stocks.

How have OPHLY shares performed in 2024?

Ono Pharmaceutical's stock was trading at $5.86 at the start of the year. Since then, OPHLY stock has decreased by 16.7% and is now trading at $4.88.
View the best growth stocks for 2024 here.

Are investors shorting Ono Pharmaceutical?

Ono Pharmaceutical saw a decrease in short interest in March. As of March 31st, there was short interest totaling 20,800 shares, a decrease of 23.8% from the March 15th total of 27,300 shares. Based on an average daily trading volume, of 199,300 shares, the short-interest ratio is currently 0.1 days.
View Ono Pharmaceutical's Short Interest.

Is Ono Pharmaceutical a good dividend stock?

Ono Pharmaceutical (OTCMKTS:OPHLY) pays an annual dividend of $16.56 per share and currently has a dividend yield of 1.43%. The dividend payout ratio is 362.62%. Payout ratios above 75% are not desirable because they may not be sustainable.

How do I buy shares of Ono Pharmaceutical?

Shares of OPHLY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:OPHLY) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
1970’s computer coder issues shocking A.I. warning
TradeSmith